These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37164987)

  • 1. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.
    Guo L; Lin S; Chen Z; Cao Y; He B; Lu G
    Signal Transduct Target Ther; 2023 May; 8(1):197. PubMed ID: 37164987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2.
    Yamamoto Y; Inoue T
    Biol Pharm Bull; 2024; 47(5):917-923. PubMed ID: 38692869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel S2 subunit-specific antibody with broad neutralizing activity against SARS-CoV-2 variants of concern.
    Heo CK; Lim WH; Yang J; Son S; Kim SJ; Kim DJ; Poo H; Cho EW
    Front Immunol; 2023; 14():1307693. PubMed ID: 38143750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
    Bi W; Chen G; Dang B
    J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.
    Xing L; Xu X; Xu W; Liu Z; Shen X; Zhou J; Xu L; Pu J; Yang C; Huang Y; Lu L; Jiang S; Liu S
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein.
    Jiao F; Andrianov AM; Wang L; Furs KV; Gonchar AV; Wang Q; Xu W; Lu L; Xia S; Tuzikov AV; Jiang S
    J Med Virol; 2023 Oct; 95(10):e29145. PubMed ID: 37804480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins.
    Polo-Megías D; Cano-Muñoz M; Berruezo AG; Laumond G; Moog C; Conejero-Lara F
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
    Lan Q; Wang L; Jiao F; Lu L; Xia S; Jiang S
    J Med Virol; 2023 Jan; 95(1):e28143. PubMed ID: 36098460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion.
    Gao J; Cao C; Shi M; Hong S; Guo S; Li J; Liang T; Song P; Xu R; Li N
    Phytomedicine; 2023 Sep; 118():154942. PubMed ID: 37421767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen.
    Wang X; Sun L; Liu Z; Xing L; Zhu Y; Xu W; Xia S; Lu L; Jiang S
    Emerg Microbes Infect; 2023 Dec; 12(2):2244084. PubMed ID: 37534910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 spike S2-specific neutralizing antibodies.
    Li CJ; Chang SC
    Emerg Microbes Infect; 2023 Dec; 12(2):2220582. PubMed ID: 37254830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein.
    Pang W; Lu Y; Zhao YB; Shen F; Fan CF; Wang Q; He WQ; He XY; Li ZK; Chen TT; Yang CX; Li YZ; Xiao SX; Zhao ZJ; Huang XS; Luo RH; Yang LM; Zhang M; Dong XQ; Li MH; Feng XL; Zhou QC; Qu W; Jiang S; Ouyang S; Zheng YT
    Cell Res; 2022 Dec; 32(12):1068-1085. PubMed ID: 36357786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.
    Zhou P; Song G; Liu H; Yuan M; He WT; Beutler N; Zhu X; Tse LV; Martinez DR; Schäfer A; Anzanello F; Yong P; Peng L; Dueker K; Musharrafieh R; Callaghan S; Capozzola T; Limbo O; Parren M; Garcia E; Rawlings SA; Smith DM; Nemazee D; Jardine JG; Safonova Y; Briney B; Rogers TF; Wilson IA; Baric RS; Gralinski LE; Burton DR; Andrabi R
    Immunity; 2023 Mar; 56(3):669-686.e7. PubMed ID: 36889306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.
    Freidel MR; Armen RS
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses.
    Chen Y; Zhao X; Zhou H; Zhu H; Jiang S; Wang P
    Nat Rev Immunol; 2023 Mar; 23(3):189-199. PubMed ID: 36168054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines.
    Guan X; Yang Y; Du L
    Expert Rev Vaccines; 2023; 22(1):422-439. PubMed ID: 37161869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
    Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
    mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.